Achillion Pharmaceuticals (ACHN) was Initiated by FBR & Co. to “Outperform” and the brokerage firm has set the Price Target at $16. FBR & Co. advised their investors in a research report released on Sep 15, 2016.
Many Wall Street Analysts have commented on Achillion Pharmaceuticals. Chardan Capital Markets Initiated Achillion Pharmaceuticals on Jul 14, 2016 to “Sell”, Price Target of the shares are set at $4.Achillion Pharmaceuticals was Upgraded by JMP Securities to ” Mkt Outperform” on Jul 7, 2016.
On the company’s financial health, Achillion Pharmaceuticals reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.15.During the same quarter in the previous year, the company posted $-0.25 EPS.
Achillion Pharmaceuticals opened for trading at $7.65 and hit $7.9 on the upside on Wednesday, eventually ending the session at $7.7, with a gain of 0.92% or 0.07 points. The heightened volatility saw the trading volume jump to 1,138,913 shares. Company has a market cap of $1,052 M.
In a different news, on Dec 30, 2015, David Apelian (Chief Medical Officer) sold 10,000 shares at $10.50 per share price. According to the SEC, on Dec 30, 2015, Mary Kay Fenton (Chief Financial Officer) sold 43,500 shares at $10.08 per share price. On Nov 12, 2015, Nicole Vitullo (director) sold 550,000 shares at $10.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.